RU2663450C2 - Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомный иринотекан - Google Patents

Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомный иринотекан Download PDF

Info

Publication number
RU2663450C2
RU2663450C2 RU2015100529A RU2015100529A RU2663450C2 RU 2663450 C2 RU2663450 C2 RU 2663450C2 RU 2015100529 A RU2015100529 A RU 2015100529A RU 2015100529 A RU2015100529 A RU 2015100529A RU 2663450 C2 RU2663450 C2 RU 2663450C2
Authority
RU
Russia
Prior art keywords
dose
irinotecan
cycle
administered
leucovorin
Prior art date
Application number
RU2015100529A
Other languages
English (en)
Russian (ru)
Other versions
RU2015100529A (ru
Inventor
Элайал БЕЙВЕР
Навреет ДХИНДСА
Джонатан Бэзил Фицджеральд
Питер ЛЕВИНС
Виктор Мойо
Клет НИЙИКИЗА
Джаэйеон КИМ
Original Assignee
Ипсен Байофарм Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48692681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2663450(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ипсен Байофарм Лтд. filed Critical Ипсен Байофарм Лтд.
Publication of RU2015100529A publication Critical patent/RU2015100529A/ru
Application granted granted Critical
Publication of RU2663450C2 publication Critical patent/RU2663450C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2015100529A 2012-06-13 2013-06-12 Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомный иринотекан RU2663450C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261659211P 2012-06-13 2012-06-13
US61/659,211 2012-06-13
US201361784382P 2013-03-14 2013-03-14
US61/784,382 2013-03-14
PCT/US2013/045495 WO2013188586A1 (en) 2012-06-13 2013-06-12 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018126616A Division RU2808427C2 (ru) 2012-06-13 2013-06-12 Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомальный иринотекан

Publications (2)

Publication Number Publication Date
RU2015100529A RU2015100529A (ru) 2016-08-10
RU2663450C2 true RU2663450C2 (ru) 2018-08-06

Family

ID=48692681

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015100529A RU2663450C2 (ru) 2012-06-13 2013-06-12 Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомный иринотекан

Country Status (21)

Country Link
US (10) US9452162B2 (cg-RX-API-DMAC7.html)
EP (3) EP3919048A1 (cg-RX-API-DMAC7.html)
JP (3) JP6310911B2 (cg-RX-API-DMAC7.html)
KR (3) KR101776808B1 (cg-RX-API-DMAC7.html)
CN (2) CN110051631A (cg-RX-API-DMAC7.html)
AU (3) AU2013202947B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014031088A8 (cg-RX-API-DMAC7.html)
CA (1) CA2875824C (cg-RX-API-DMAC7.html)
DK (2) DK2861210T3 (cg-RX-API-DMAC7.html)
ES (2) ES2880089T3 (cg-RX-API-DMAC7.html)
IL (3) IL235937B (cg-RX-API-DMAC7.html)
IN (1) IN2014DN11099A (cg-RX-API-DMAC7.html)
MX (1) MX376937B (cg-RX-API-DMAC7.html)
NZ (1) NZ702469A (cg-RX-API-DMAC7.html)
PL (2) PL2861210T3 (cg-RX-API-DMAC7.html)
PT (2) PT3266456T (cg-RX-API-DMAC7.html)
RU (1) RU2663450C2 (cg-RX-API-DMAC7.html)
SI (2) SI3266456T1 (cg-RX-API-DMAC7.html)
TW (3) TWI630924B (cg-RX-API-DMAC7.html)
WO (1) WO2013188586A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408804B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4218730B1 (en) 2004-05-03 2023-11-01 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
JP6758195B2 (ja) * 2014-01-14 2020-09-23 ネクター セラピューティクス 併用ベースの治療方法
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
WO2016094402A1 (en) * 2014-12-09 2016-06-16 Merrimack Pharmaceuticals, Inc. Treatment of breast cancer with liposomal irinotecan
TW201701880A (zh) * 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
SG10201913073YA (en) * 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
US20170049775A1 (en) * 2015-08-21 2017-02-23 Merrimack Pharmaceuticals, Inc. Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
US10894044B2 (en) 2015-09-16 2021-01-19 Board Of Regents, The University Of Texas System Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
CN114099437A (zh) 2015-10-16 2022-03-01 易普森生物制药有限公司 稳定喜树碱药物组合物
WO2017172678A1 (en) * 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
CN109640995A (zh) * 2016-05-18 2019-04-16 易普森生物制药有限公司 用脂质体伊立替康治疗小细胞肺癌
RU2761953C2 (ru) * 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
CN113164600A (zh) * 2018-10-17 2021-07-23 百欧林纳克斯有限公司 转移性胰脏腺癌的治疗
WO2020148744A1 (en) * 2019-01-17 2020-07-23 Biolinerx Ltd. Combination therapy for treatment of pancreatic cancer
US20220072087A1 (en) * 2019-01-17 2022-03-10 Biolinerx Ltd. Specific combination therapy for treatment of pancreatic cancer
US11286344B2 (en) 2020-01-10 2022-03-29 Tyndall Formulation Services, LLC Polymer excipients for drug delivery applications
WO2021142020A1 (en) * 2020-01-10 2021-07-15 Tyndall Formulation Services, LLC Formulations of sn-38 with poly(amino acid) block polymers
WO2021142202A1 (en) 2020-01-10 2021-07-15 R-Pharm Us Operating Llc Compositions of ixabepilone
CN118302192A (zh) * 2021-10-03 2024-07-05 西雅图免疫公司 治疗癌症的方法及其药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076117A2 (en) * 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2628659A (en) * 1951-01-17 1953-02-17 Charles R Carpenter Convertible furniture article
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (de) 1996-01-31 1997-08-07 Schering Ag Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
AU4990397A (en) 1996-10-22 1998-05-15 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6355268B1 (en) 1998-09-16 2002-03-12 Alza Corporation Liposome-entrapped topoisomerase inhibitors
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US7025988B2 (en) 2000-02-04 2006-04-11 Lipoxen Technologies Limited Liposomes
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
AU2001261473B2 (en) 2000-05-15 2006-09-14 Board Of Trustees Of The University Of Arkansas Compositions and methods for the treatment of colorectal cancer
MXPA02012817A (es) 2000-06-30 2004-07-30 Inex Pharmaceuticals Inc Drogas antineoplasicas liposomales y uso de las mismas.
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
AU2002305094B2 (en) 2001-03-26 2007-01-11 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
JP2005505526A (ja) 2001-07-23 2005-02-24 エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト Ｕｇｔ１ａ１に基づいたがんの改善治療の手段及び方法
US20030077833A1 (en) * 2001-09-07 2003-04-24 Queen's University At Kingston Diagnositc methods for determining susceptibility to convulsive conditions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
ITBO20010610A1 (it) 2001-10-05 2003-04-05 Haworth S P A Dispositivo per la connessione di gambe ad elementi di arredamento, ed elemento di arredamento comprendente tale dispositivo
CA2752143C (en) 2002-05-15 2014-09-23 Sutter West Bay Hospitals Delivery of nucleic acid-like compounds
ATE458751T1 (de) 2002-05-31 2010-03-15 Transmolecular Inc Kombinationschemotherapie mit chlorotoxin
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
EP4218730B1 (en) 2004-05-03 2023-11-01 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
US7846473B2 (en) 2004-06-01 2010-12-07 Terumo Kabushiki Kaisha Irinotecan preparation
BRPI0511800A (pt) 2004-06-03 2008-01-15 Hoffmann La Roche tratamento com irinotecano (cpt-11) e um inibidor de egfr
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
AU2006306108B2 (en) 2005-10-25 2012-10-04 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
JP2009515884A (ja) * 2005-11-10 2009-04-16 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性の阻害剤
DK2338487T3 (da) 2006-01-17 2013-12-09 Abbvie Bahamas Ltd Kombinationsterapi med PARP-inhibitorer
CN101442998B (zh) 2006-03-16 2012-03-14 比奥纽默里克药物公司 抗癌活性加强化合物和制剂及其用法
CN101506362B (zh) * 2006-11-30 2012-09-05 爱科来株式会社 Ugt1a1基因扩增用引物对、含有其的ugt1a1基因扩增用试剂及其用途
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
ES2550759T3 (es) 2007-08-17 2015-11-12 Celator Pharmaceuticals, Inc. Formulaciones farmacológicas de platino mejoradas
US20100239652A1 (en) 2007-09-28 2010-09-23 Universitatsspital Basel Immunoliposomes for treatment of cancer
CA2705417A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
EP2224804A4 (en) 2007-12-07 2011-06-01 Bipar Sciences Inc TREATMENT OF CANCER WITH COMBINATIONS OF TOPOÎSOMERASE INHIBITORS AND PARP INHIBITORS
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
EP2259797A2 (en) 2008-03-25 2010-12-15 Schering Corporation Methods for treating or preventing colorectal cancer
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
EP2860260A1 (en) 2008-04-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
US9463193B2 (en) 2008-09-26 2016-10-11 Institut De Cancerologie De L'ouest Individual 5-fluorouracile dose optimization in folfiri treatment
KR20110112301A (ko) 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
EP2424516A4 (en) 2009-05-01 2014-04-02 Oncozyme Pharma Inc PENTAMIDINE COMBINATIONS FOR THE TREATMENT OF CANCER
KR20120089754A (ko) 2009-12-03 2012-08-13 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 이리노테칸 또는 그의 하이드로클로라이드의 리포좀 및 그의 제조 방법
EP2575804A4 (en) 2010-06-04 2013-10-23 Abraxis Bioscience Llc METHOD FOR THE TREATMENT OF PANCREASCRE
JP2013531068A (ja) 2010-07-19 2013-08-01 バイパー サイエンシズ，インコーポレイティド ４−ヨード−３−ニトロベンズアミドを抗腫瘍剤と組み合わせて用いる乳癌の治療方法
MX349662B (es) 2010-07-22 2017-08-08 Univ California Anticuerpos de antigenos antitumorales y metodos de uso.
RU2541100C2 (ru) 2010-09-03 2015-02-10 Боард Оф Регентс Оф Зе Юниверсити Оф Небраска Способ и композиция для лечения рака
JP6208582B2 (ja) 2010-12-06 2017-10-04 メリマック ファーマシューティカルズ インコーポレーティッド アントラサイクリン系化学療法剤を含有しているｅｒｂｂ２標的免疫リポソームによる治療における心臓毒性を抑制するための用量及び投与
WO2012079582A1 (en) 2010-12-14 2012-06-21 Technical University Of Denmark Entrapment of radionuclides in nanoparticle compositions
AU2012217685B2 (en) 2011-02-15 2017-05-18 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
HRP20170713T1 (hr) 2011-04-19 2017-07-14 Merrimack Pharmaceuticals, Inc. Bispecifično anti-igf-1r i anti-erbb3 antitijelo
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
AU2013201584A1 (en) * 2012-03-12 2013-09-26 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody
KR20150050524A (ko) 2012-04-17 2015-05-08 메리맥 파마슈티컬즈, 인크. 비침습적 이미징을 위한 조성물 및 방법
US9717724B2 (en) * 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2014113167A1 (en) 2012-12-14 2014-07-24 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
HUE041687T2 (hu) 2013-03-27 2019-05-28 Taiho Pharmaceutical Co Ltd Antitumor szer, amely tartalmaz kis dózisú irinotekan-hidroklorid-hidrát-ot
EP3038600B1 (en) 2013-08-27 2020-06-03 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
WO2015061592A1 (en) 2013-10-23 2015-04-30 Merrimack Pharmaceuticals, Inc. Liposomes for non-invasive imaging and drug delivery
WO2016094402A1 (en) 2014-12-09 2016-06-16 Merrimack Pharmaceuticals, Inc. Treatment of breast cancer with liposomal irinotecan
TW201701880A (zh) 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
US20170049775A1 (en) 2015-08-21 2017-02-23 Merrimack Pharmaceuticals, Inc. Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
CN114099437A (zh) 2015-10-16 2022-03-01 易普森生物制药有限公司 稳定喜树碱药物组合物
US20170202840A1 (en) 2016-01-14 2017-07-20 Merrimack Pharmaceuticals, Inc. Treatment of pancreatic cancer with liposomal irinotecan
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
US20170333421A1 (en) 2016-05-18 2017-11-23 Ipsen Biopharm Ltd. Population Pharmacokinetics of Liposomal Irinotecan
CN109640995A (zh) 2016-05-18 2019-04-16 易普森生物制药有限公司 用脂质体伊立替康治疗小细胞肺癌
RU2761953C2 (ru) 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076117A2 (en) * 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHANG-SUNG TSAI et al., Nanovector-based therapies in advanced pancreatic cancer, Journal of Gastrointestinal Oncology, 2011, Vol 2, N 3, Р. 185-194, Найдено из Интернета [он-лайн] на сайте http://jgo.amegroups.com/article/view/223;. *
CHANG-SUNG TSAI et al., Nanovector-based therapies in advanced pancreatic cancer, Journal of Gastrointestinal Oncology, 2011, Vol 2, N 3, Р. 185-194, Найдено из Интернета [он-лайн] на сайте http://jgo.amegroups.com/article/view/223;. HOSKINS J. M. et al., UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters, Journal of the national cancer institute, 2007, vol. 99, N 17, P. 1290 - 1295, Найдено из Интернета [он-лайн] на сайте https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djm115. HEDIA BRIXI-BENMANSOUR et al., Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma, Digestive and liver disease, 2011, vol. 43, no. 11, Р. 912-916. O'DWYER P.J. et al., Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy, J Clin Oncol. 2006 Oct 1;24(28):4534-8. *
HEDIA BRIXI-BENMANSOUR et al., Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma, Digestive and liver disease, 2011, vol. 43, no. 11, Р. 912-916. *
HOSKINS J. M. et al., UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters, Journal of the national cancer institute, 2007, vol. 99, N 17, P. 1290 - 1295, Найдено из Интернета [он-лайн] на сайте https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djm115. *
O'DWYER P.J. et al., Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy, J Clin Oncol. 2006 Oct 1;24(28):4534-8. *

Also Published As

Publication number Publication date
AU2013274287A1 (en) 2015-01-29
CA2875824C (en) 2021-05-18
TWI630924B (zh) 2018-08-01
HK1209627A1 (en) 2016-04-08
US9364473B2 (en) 2016-06-14
NZ702469A (en) 2017-08-25
BR112014031088A8 (pt) 2021-06-22
WO2013188586A1 (en) 2013-12-19
MX2014015391A (es) 2015-06-17
US20220096458A1 (en) 2022-03-31
TWI729492B (zh) 2021-06-01
MX376937B (es) 2025-03-07
US9339497B2 (en) 2016-05-17
US20150328156A1 (en) 2015-11-19
JP2017149783A (ja) 2017-08-31
IN2014DN11099A (cg-RX-API-DMAC7.html) 2015-09-25
ES2632915T3 (es) 2017-09-18
JP2019116517A (ja) 2019-07-18
US20160074382A1 (en) 2016-03-17
US20190117643A1 (en) 2019-04-25
IL294886A (en) 2022-09-01
US9452162B2 (en) 2016-09-27
DK2861210T3 (en) 2017-07-24
AU2013202947B2 (en) 2016-06-02
ZA201408804B (en) 2017-06-28
IL235937B (en) 2022-08-01
US9492442B2 (en) 2016-11-15
EP3919048A1 (en) 2021-12-08
CN110051631A (zh) 2019-07-26
SI2861210T1 (sl) 2017-10-30
US20240226090A1 (en) 2024-07-11
EP3266456A1 (en) 2018-01-10
HK1248608A1 (en) 2018-10-19
US10980795B2 (en) 2021-04-20
KR101997206B1 (ko) 2019-07-08
BR112014031088A2 (pt) 2017-06-27
AU2013274287B2 (en) 2017-12-21
PT2861210T (pt) 2017-07-26
PL3266456T3 (pl) 2021-11-29
AU2018201942B2 (en) 2019-12-05
SI3266456T1 (sl) 2022-03-31
KR20190107010A (ko) 2019-09-18
US20150182521A1 (en) 2015-07-02
TW201831168A (zh) 2018-09-01
JP6310911B2 (ja) 2018-04-11
IL304631A (en) 2023-09-01
TW201412345A (zh) 2014-04-01
AU2013202947A1 (en) 2014-01-16
EP2861210B1 (en) 2017-05-03
IL235937A0 (en) 2015-01-29
DK3266456T3 (da) 2021-07-05
US20160228428A1 (en) 2016-08-11
PT3266456T (pt) 2021-07-28
US20170368056A1 (en) 2017-12-28
KR20150021565A (ko) 2015-03-02
KR20170104638A (ko) 2017-09-15
RU2015100529A (ru) 2016-08-10
JP2015523355A (ja) 2015-08-13
AU2018201942A1 (en) 2018-04-12
PL2861210T3 (pl) 2017-12-29
KR101776808B1 (ko) 2017-09-11
JP6857210B2 (ja) 2021-04-14
EP3266456B1 (en) 2021-05-05
TW202027727A (zh) 2020-08-01
CN104717961A (zh) 2015-06-17
ES2880089T3 (es) 2021-11-23
EP2861210A1 (en) 2015-04-22
US20170065578A1 (en) 2017-03-09
CA2875824A1 (en) 2013-12-19
US20150374682A1 (en) 2015-12-31
RU2018126616A (ru) 2019-03-12

Similar Documents

Publication Publication Date Title
RU2663450C2 (ru) Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомный иринотекан
RU2808427C2 (ru) Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомальный иринотекан
HK40064914A (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
HK1248608B (en) Combinations of liposomal irinotecan, 5-fu and leucovorin for the treatment of pancreatic cancer
HK1209627B (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Legal Events

Date Code Title Description
HC9A Changing information about inventors
HZ9A Changing address for correspondence with an applicant